Anand Balakrishnan

About

I am passionate about scientific research addressing global public health issues, especially infectious diseases. I study enzymes that constitute the genetic replication and transcription machinery of viral pathogens. My current research aims to target these enzymes and discover novel antiviral drugs.

Expertise
• Biochemistry • Molecular Pharmacology • Drug Discovery

Employment

• AbbVie (United States) Principal Scientist
  2023 - Present
• Enanta Pharmaceuticals (United States) Principal Scientist
  2018 - 2022
• Novartis Institutes for BioMedical Research Inc Investigator
  2015 - 2018
• Weill Cornell Medicine Postdoctoral Associate
  2011 - 2015

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Discovery of Potent and Orally Bioavailable Novel Cluster of Differentiation 38 (CD38) Small Molecule Inhibitors
  Journal of Medicinal Chemistry 2026 DOI: 10.1021/acs.jmedchem.6c00171
  +Save
• SARS-CoV-2 resistance pathways to EDP-235
  Antiviral Research 2026 DOI: 10.1016/j.antiviral.2026.106493
  +Save
• The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo
  Nature Communications 2024 DOI: 10.1038/s41467-024-50931-8
  +Save
• Discovery and Characterization of Hydroxysteroid 17-β Dehydrogenase 13 Inhibitors
  Hepatology 2022 DOI: 10.1002/hep.32697
  +Save
• Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury
  The International Liver Congress 2022
  +Save
• Molecular Basis for Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of Covid 19.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022 DOI: 10.1096/fasebj.2022.36.s1.0r514
  +Save
• Biochemical characterization of respiratory syncytial virus RNA-dependent RNA polymerase complex
  ACS Infectious Diseases 2020 DOI: 10.1021/acsinfecdis.0c00554
  +Save
• Comparison of transposon and deletion mutants in Mycobacterium tuberculosis: The case of rv1248c, encoding 2-hydroxy-3-oxoadipate synthase.
  Tuberculosis (Edinburgh, Scotland) 2015 DOI: 10.1016/j.tube.2015.08.009
  +Save
• E1 of α-ketoglutarate dehydrogenase defends Mycobacterium tuberculosis against glutamate anaplerosis and nitroxidative stress.
  Proceedings of the National Academy of Sciences of the United States of America 2015 DOI: 10.1073/pnas.1510932112
  +Save
• Influence of allosteric regulators on individual steps in the reaction catalyzed by mycobacterium tuberculosis 2-hydroxy-3-oxoadipate synthase
  Journal of Biological Chemistry 2013 DOI: 10.1074/jbc.M113.465419
  +Save